Recommended Medications for Social Anxiety Disorder
For adults with social anxiety disorder, start with an SSRI (selective serotonin reuptake inhibitor) as first-line pharmacotherapy, with specific agents including escitalopram, paroxetine, sertraline, or fluvoxamine. 1
First-Line Pharmacotherapy
The most recent clinical practice guidelines (2023) provide clear recommendations for medication selection:
SSRIs - Primary Recommendation
SSRIs are the cornerstone of pharmacological treatment for social anxiety disorder 1. While the guideline recommendation is graded as "weak" with "low" certainty of evidence (GRADE 2C), this reflects the nature of psychiatric research rather than lack of efficacy. In clinical practice, SSRIs should be your default first choice because they:
- Demonstrate consistent treatment response across multiple trials (26 RCTs supporting their use) 1
- Are effective for reducing both social anxiety symptoms and commonly comorbid depression 2
- Have acceptable tolerability profiles with low absolute withdrawal rates despite being higher than placebo 2
- Are the only medication class proven effective in preventing relapse 2
Specific SSRI agents recommended across international guidelines:
- Escitalopram and sertraline: Listed as first-line by NICE guidelines 1
- Paroxetine: Shows the strongest evidence for symptom reduction and treatment response in network meta-analysis 3, and is listed as standard therapy by German S3 guidelines 1
- Fluvoxamine: Approved in Japan and listed as first-line by Canadian guidelines 1
SNRIs - Alternative First-Line Option
Venlafaxine (extended-release) is the only SNRI with evidence for social anxiety disorder 1. It represents a reasonable alternative to SSRIs, particularly if:
- Patient has failed an adequate SSRI trial
- Comorbid conditions favor SNRI use
- Patient preference after discussing options
However, note that venlafaxine has higher withdrawal rates due to adverse events compared to placebo (RR 3.23) 2, though this must be balanced against its efficacy.
Practical Prescribing Algorithm
Step 1: Initial Treatment
- Begin with an SSRI (escitalopram, sertraline, paroxetine, or fluvoxamine)
- Allow 8-12 weeks for adequate trial at therapeutic dose
- Monitor for treatment response using validated scales
Step 2: If Inadequate Response to First SSRI
- Switch to a different SSRI, OR
- Switch to venlafaxine ER 1
- German S3 guidelines specifically recommend switching to another standard drug if first choice inadequate 1
Step 3: Treatment-Resistant Cases The evidence base becomes limited here, but Canadian guidelines provide second-line options 1:
- Pregabalin (anticonvulsant with GABA analogue properties): Moderate-quality evidence for efficacy 2
- Benzodiazepines (alprazolam, bromazepam, clonazepam): Strong short-term efficacy (RR 4.03) 2, but reserve for specific situations due to dependence risk
- Gabapentin: Listed as second-line option 1
Duration of Treatment
Continue medication for at least 12-20 weeks after achieving response. Patients who discontinue treatment earlier show higher relapse rates than those who continue 4. The SSRIs are the only medication class with evidence supporting relapse prevention 2.
Important Clinical Caveats
What NOT to use:
- Beta-blockers (atenolol, propranolol): Negative evidence, specifically deprecated by Canadian guidelines 1
- Antipsychotics (quetiapine): Not recommended despite some studies 1
- Tricyclic antidepressants (imipramine): Negative evidence 1
Combination therapy: There is no recommendation for combining pharmacotherapy with psychotherapy based on current evidence 1. This doesn't mean it's harmful, but evidence doesn't support routine combination as superior to monotherapy.
Benzodiazepine considerations: While benzodiazepines show strong efficacy (RR 4.03 for treatment response) 2, they should be reserved for:
- Acute symptom management while waiting for SSRI/SNRI onset
- Treatment-resistant cases after other options exhausted
- Short-term use only due to dependence potential
Monitoring requirements: Treatment should be monitored by a physician with expertise in social anxiety disorder diagnosis and management 1. This is particularly important given the high rates of comorbid psychiatric conditions (approximately one-third of patients) 1.
Quality of Evidence Considerations
The evidence base for social anxiety disorder pharmacotherapy has important limitations. Most recommendations carry "weak" strength with "low" certainty evidence 1. This reflects:
- Heterogeneity in study populations and outcome measures
- Limited head-to-head comparison trials
- Few studies addressing treatment-resistant cases 1
Despite these limitations, the consistency of SSRI efficacy across 24 RCTs involving nearly 5,000 participants provides sufficient evidence for confident first-line use 2. The network meta-analysis identifying paroxetine as most effective offers additional guidance for agent selection 3.